- |||||||||| Clinical, Journal: Thymolipoma Association with Myasthenia Gravis: Case Report. (Pubmed Central) - May 15, 2021
Concomitant heart surgery and thymectomy are feasible, and extended thymectomy is the treatment of choice for thymolipoma in myasthenia gravis patients with a better complete remission rate after resection. However, further comparative studies are needed for a more reliable conclusion of the postoperative myasthenia gravis response after resection.
- |||||||||| imatinib / Generic mfg.
Clinical, Review, Journal, Checkpoint inhibition: Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. (Pubmed Central) - May 15, 2021
The first patient was treated with the combination of Vemurafenib and Cobimetinib, BRAF and MEK inhibitors, respectively, for a cutaneous melanoma...The second patient received therapy with Imatinib, tyrosine kinase inhibitor and precursor of the targeted therapy, for a gastrointestinal stromal tumour...DISCUSSION AND We strengthen the relevance of neuromuscular complications which may occur long after treatment start or in patients receiving not only the latest ICPi but also "older" and apparently better-known targeted therapies. Also in the latter cases, an immune-mediated "off-target" pathogenic mechanism can be hypothesized, and consequences can be life threatening, if not promptly diagnosed and appropriately managed.
- |||||||||| sotrastaurin (AEB071) / Novartis
Preclinical, Journal: AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model. (Pubmed Central) - May 15, 2021
Although a decrease in the number of Treg cells was observed, the proportion of Th lymphocytes was significantly increased in the EAMG group, and AEB-071 treatment decreased the proportion of Th lymphocytes. CONCLUSIONS We concluded that AEB-071 treatment imparts beneficial effects in EAMG rat models by reducing mortality rate and restoring Th lymphocyte balance, and thus may be an attractive candidate for use in MG treatment.
- |||||||||| mycophenolate mofetil / Generic mfg.
Clinical, Journal: Pyoderma gangrenosum wıth thymoma and myasthenıa gravıs: A case report. (Pubmed Central) - May 15, 2021
The purpose of treatment is; to control the lesions and related diseases for a long time with minimal side effects. Mycophenolate mofetil treatment was used safely and successfully for both generalized MG and PG in our case.
- |||||||||| Clinical, Journal: A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth hormone deficiency and hyperthyroidism in a patient with pseudo-Turner's syndrome. (Pubmed Central) - May 15, 2021
The principal manifestations of APS-3 are autoimmune thyroid disease and other autoimmune diseases, such as type 1 diabetes, atrophic gastritis, pernicious anemia, vitiligo, alopecia, and myasthenia gravis, but not Addison's disease or hypoparathyroidism. Here we report a case demonstrating the rare coexistence of growth hormone deficiency and hyperthyroidism with sexual dysgenesis, secondary amenorrhea, cardiomegaly, splenomegaly, hypoproteinemia, pleural effusion, seroperitoneum, pericardial effusion, anasarca, osteoporosis, vitamin D deficiency, iron-deficiency anemia, poor blood coagulation, leucocytopenia, peripheral neuropathy, hyperuricemia, ichthyosis, tinea cruris, and onychomycosis.
- |||||||||| dexamethasone injection / Generic mfg.
Journal: Local use of dexamethasone in the treatment of ocular myasthenia gravis. (Pubmed Central) - May 15, 2021
As such, it should be on the differential list for poorly-responsive hypotension following a shift in body positioning under anesthesia. Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy.
- |||||||||| Review, Journal: Benefit and danger from immunotherapy in myasthenia gravis. (Pubmed Central) - May 15, 2021
This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
- |||||||||| Journal: Increasead cholinergic tone causes pre-synaptic neuromuscular degeneration and is associated with impaired diaphragm function. (Pubmed Central) - May 15, 2021
Finally, we showed that ChAT-ChR2-EYFP mice NMJs have compromised safety, possible due to the structural alterations we described. These findings reveal that physiological cholinergic activity is important to maintain the structure and function of the neuromuscular system and help to understand some of the neuromuscular adverse effects experienced by chronically increased NMJ neurotransmission, such as individuals treated with cholinesterase inhibitors.
- |||||||||| Journal: Hemisensory loss in myasthenia gravis. (Pubmed Central) - May 15, 2021
Serum and electrodiagnostic studies confirmed the diagnosis of myasthenia gravis. This case highlights the non-classic presentation of myasthenia gravis in the absence of ophthalmoplegia with a unique unexplained hemisensory deficit.
- |||||||||| Journal: Myasthenia (Pubmed Central) - May 15, 2021
This case highlights the non-classic presentation of myasthenia gravis in the absence of ophthalmoplegia with a unique unexplained hemisensory deficit. No abstract available
- |||||||||| sulfasalazine / Generic mfg.
Review, Journal: Neurology of inflammatory bowel disease. (Pubmed Central) - May 15, 2021
The pathophysiology of neurological manifestations of IBD is mostly immune mediated, but dysfunction of the brain-gut axis, arterial and venous thromboembolism, infections, nutritional deficiencies and side-effects of medications (steroids, metronidazole, sulfasalazine, anti-TNF-α, anti-integrin antibodies) are other contributory mechanisms...Optic neuritis, transverse myelitis, progressive myelopathy, central nervous system infections, epilepsy and encephalopathy are among other uncommon neurological complications. Peripheral nervous system manifestations include peripheral neuropathy, either demyelination and axonal, myasthenia gravis and polymyositis/dermatomyositis and localized forms of myositis.
- |||||||||| Journal: Myasthenia Gravis Revealing Hodgkin's Lymphoma. (Pubmed Central) - May 15, 2021
The association of lymphomas with myasthenia gravis has been rarely reported. Myasthenia gravis is an autoimmune disease of the neuromuscular junction and can be associated with malignant haemopathy.The coexistence of myasthenia and Hodgkin's lymphoma is very rare.This association is a therapeutic challenge.
- |||||||||| Review, Journal: Collagens at the vertebrate neuromuscular junction, from structure to pathologies. (Pubmed Central) - May 14, 2021
A number of neuromuscular diseases, congenital myastenic syndromes and myasthenia gravis are caused by human mutations and autoantibodies against these proteins. Analysis of these diseases and of the specific collagen knock-out mice highlights the roles of some of these collagens in promoting a functional synapse.
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
Clinical, Journal: A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone. (Pubmed Central) - May 14, 2021
Analysis of these diseases and of the specific collagen knock-out mice highlights the roles of some of these collagens in promoting a functional synapse. This case report illustrates early use of the combination therapy might be beneficial in refractory myasthenia gravis cases even with chronic immunosuppression and severe COVID-19 infection.
- |||||||||| Review, Journal: Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology. (Pubmed Central) - May 13, 2021
We also discuss three secreted molecules (Rspo2, Fgf18, and connective tissue growth factor (Ctgf)) that we recently identified in the Wnt/β-catenin and fibroblast growth factors (FGF) signaling pathways. The three secreted molecules facilitate the clustering of AChRs by enhancing the agrin-Lrp4-MuSK signaling pathway.
- |||||||||| Clinical, Clinical guideline, Journal: Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. (Pubmed Central) - May 13, 2021
Before the publication of these guidelines, no comprehensive clinical care guidelines existed for treating botulism. These evidence-based guidelines provide health care providers with recommended best practices for diagnosing, monitoring, and treating single cases or outbreaks of foodborne, wound, and inhalational botulism and were developed after a multiyear process involving several systematic reviews and expert input.
- |||||||||| nipocalimab (M281) / J&J
Trial completion date, Trial primary completion date: An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - May 13, 2021
P2, N=37, Terminated,
These evidence-based guidelines provide health care providers with recommended best practices for diagnosing, monitoring, and treating single cases or outbreaks of foodborne, wound, and inhalational botulism and were developed after a multiyear process involving several systematic reviews and expert input. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
Journal: Inhibitors of Cholinesterases in the Pharmacology, the Current Trends. (Pubmed Central) - May 6, 2021
This review is focused on survey of cholinesterase inhibitors with known or expected pharmacological impact and indications of their use. Recent literature with comments on it is provided here as well.
- |||||||||| Journal: Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant. (Pubmed Central) - May 1, 2021
This suggests that p.(Arg247Gln) is associated with a relatively mild CMS phenotype with subtle mitochondrial abnormalities, while other variants in this gene cause more severe neurometabolic disease. In conclusion, the p.(Arg247Gln) SLC25A1 variant should be considered in patients presenting with a presynaptic CMS phenotype, particularly with accompanying intellectual disability.
- |||||||||| Bridion (sugammadex) / Merck (MSD)
Review, Journal: Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. (Pubmed Central) - May 1, 2021
Other drugs, especially certain antibiotics, antiarrhythmics, anesthetics and neuromuscular blockers, have deleterious effects on neuromuscular transmission, resulting in increased weakness in MG or MG-like symptoms in patients who do not have MG, with the latter usually being under medical circumstances such as kidney failure. This review summarizes the drugs which can cause de novo MG, MG exacerbation or MG-like symptoms in nonmyasthenic patients.
- |||||||||| Review, Journal: Diagnosis of Myasthenia Gravis. (Pubmed Central) - May 1, 2021
Ancillary bedside tests and laboratory methods help confirm the synaptic disorder, define its type and severity, classify MG according to the causative antibodies, and assess the effect of treatment objectively. We present an update on the tests used in the diagnosis and follow-up of MG and the suggested approach for their application.
- |||||||||| Clinical, Journal: Pronounced Ptosis in Myasthenia Gravis-A New Bedside Clinical Sign. (Pubmed Central) - May 1, 2021
The loss of compensation for ptosis by frontalis muscle due to speech-induced fatigue may be responsible for the observed effect. Patients' symptoms abated on treatment with acetylcholine esterase inhibitors, steroids, and steroid-sparing agents.
- |||||||||| Journal: Afterdischarges in Myasthenia Gravis. (Pubmed Central) - May 1, 2021
The afterdischarges occurred on the first stimulation, but decreased on the second and subsequent stimulations in patients with MuSK-MG, while the afterdischarges continued to occur on each stimulation in patients with AchR-MG. The characteristics of the afterdischarges on RNS enabled easy identification of their synaptic or neurogenic nature.
|
